Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ICHOR HOLDINGS, LTD.ICHR · Entity 4529 | Director | May 15, 2024 | May 17, 2024 |
| LAM RESEARCH CORPLRCX · Entity 1467 | Chief Legal Officer & SVP | December 19, 2019 | December 23, 2019 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ICHOR HOLDINGS, LTD.
Report date May 15, 2024 · Filed May 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 28,325 |
Reported balance
After 2024-05-15 transaction · row 1
1 source rowRow 1 · 2024-05-15 · Grant · Acquired 3,923 · Balance 28,325 F1: Consists of an RSU grant, representing the right to receive Ordinary Shares of Ichor Holdings, Ltd. The RSU vests in full on May 9, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of an RSU grant, representing the right to receive Ordinary Shares of Ichor Holdings, Ltd. The RSU vests in full on May 9, 2025.
LAM RESEARCH CORP
Report date December 19, 2019 · Filed December 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,084 |
Reported balance
After 2019-12-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-12-19 · Sale · Disposed 3,831 · Balance 32,084 F1: The reporting person contributed LRCX common stock to an exchange fund in exchange for shares of the exchange fund. The LRCX common stock was valued at $287.804 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F2: Amount reported includes shares subject to unvested Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person contributed LRCX common stock to an exchange fund in exchange for shares of the exchange fund. The LRCX common stock was valued at $287.804 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person.
F2: Amount reported includes shares subject to unvested Restricted Stock Units.
Protagonist Therapeutics, Inc
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,825 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 2,695 · Balance 7,825 F1: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.18 · Expires 2036-01-02 | Direct | 3,762 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 3,762 · Balance 3,762 F2: The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date.
F2: The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 19:39 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 3,762 | $0.00 Strike: $87.18 | $0.00 |
DisclosureSEC source: 0001104659-26-001475 · tm262304-4_4seq1.xml · derivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,762 Underlying: Common Stock · 3,762 shares Expires 2036-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 19:39 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 2,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-001475 · tm262304-4_4seq1.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,825 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 18:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 6,584 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001434 · tm252003-7_4seq1.xml · derivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,584 Underlying: Common Stock · 6,584 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 18:10 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001434 · tm252003-7_4seq1.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,130 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| May 15, 2024 Filed May 17, 2024 16:18 UTC | ICHOR HOLDINGS, LTD. ICHR · Entity 4529 | GrantOrdinary Shares, par value $0.0001 | 3,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-024072 · wk-form4_1715977105.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,325 F1 · shares: Consists of an RSU grant, representing the right to receive Ordinary Shares of Ichor Holdings, Ltd. The RSU vests in full on May 9, 2025. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 20:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 25,700 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001104659-24-001496 · tm241954-8_4seq1.xml · derivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,700 Underlying: Common Stock · 25,700 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| May 18, 2023 Filed May 22, 2023 17:58 UTC | ICHOR HOLDINGS, LTD. ICHR · Entity 4529 | GrantOrdinary Shares, par value $0.0001 | 4,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-019332 · wk-form4_1684792698.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,402 F1 · shares: Consists of an RSU grant, representing the right to receive Ordinary Shares of Ichor Holdings, Ltd. The RSU vests in full on May 10, 2024. Read SEC document |
| January 16, 2023 Filed Jan 18, 2023 20:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-23-004732 · tm233829-2_4seq1.xml · derivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-15 F1 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following the date of grant. Read SEC document |
| May 26, 2022 Filed May 27, 2022 16:02 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001104659-22-065866 · tm2214526-7_4seq1.xml · derivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-26 F1 · derivative.exercise_date: The stock option vests in full on the earlier of (i) May 26, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| May 24, 2022 Filed May 26, 2022 17:44 UTC | ICHOR HOLDINGS, LTD. ICHR · Entity 4529 | GrantOrdinary Shares, par value $0.0001 | 5,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032302 · doc4.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,650 F1 · shares: Consists of an RSU grant, representing the right to receive Ordinary Shares of Ichor Holdings, Ltd. The RSU vests in full on May 12, 2023. Read SEC document |
| May 27, 2021 Filed May 28, 2021 18:50 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $35.23 | $0.00 |
DisclosureSEC source: 0001209191-21-036664 · doc4.xml · derivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-05-26 F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier of (i) May 27, 2022, or (ii) the date of the 2022 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan). Read SEC document |
| May 11, 2021 Filed May 14, 2021 17:42 UTC | ICHOR HOLDINGS, LTD. ICHR · Entity 4529 | GrantOrdinary Shares, par value $0.0001 | 2,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032851 · doc4.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,015 F1 · shares: Consists of an RSU grant, representing the right to receive Ordinary Shares of Ichor Holdings, Ltd. The RSU vests in full on May 11, 2022. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 17:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.50 | $0.00 |
DisclosureSEC source: 0001209191-20-047246 · doc4.xml · derivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-08-16 F1 · derivative.exercise_date: The shares subject to the option shall vest in 36 equal monthly installments from the vesting commencement date of August 12, 2020. Read SEC document |
| May 12, 2020 Filed May 14, 2020 16:58 UTC | ICHOR HOLDINGS, LTD. ICHR · Entity 4529 | GrantOrdinary Shares, par value $0.0001 | 4,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029217 · doc4.xml · nonDerivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,489 F2 · shares: Consists of an RSU grant, representing the right to receive Ordinary Shares of Ichor Holdings, Ltd. The RSU vests in full on May 10, 2021. Read SEC document |
| May 12, 2020 Filed May 14, 2020 16:58 UTC | ICHOR HOLDINGS, LTD. ICHR · Entity 4529 | GrantOrdinary Shares, par value $0.0001 | 6,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029217 · doc4.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,893 F1 · shares: Consists of an RSU grant, representing the right to receive Ordinary Shares of Ichor Holdings, Ltd. The RSU vests as follows: 25% vests on May 12, 2021 and the remainder vests ratably on a quarterly basis over a two-year period thereafter. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 22:10 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | SaleCommon Stock | 3,831 | $287.80 | $1,102,577.12 |
DisclosureSEC source: 0000707549-19-000208 · wf-form4_157713903955706.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,084 F1 · kind: The reporting person contributed LRCX common stock to an exchange fund in exchange for shares of the exchange fund. The LRCX common stock was valued at $287.804 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F1 · price: The reporting person contributed LRCX common stock to an exchange fund in exchange for shares of the exchange fund. The LRCX common stock was valued at $287.804 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F2 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 19:01 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 22,140 | $42.61 Strike: $42.61 | $943,385.40 |
DisclosureSEC source: 0000707549-19-000145 · wf-form4_156840125508171.xml · derivative · entry 3 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,140 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options fully vested on 2/08/15. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 19:01 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | SaleCommon Stock | 22,140 | $233.77 | $5,175,623.52 |
DisclosureSEC source: 0000707549-19-000145 · wf-form4_156840125508171.xml · nonDerivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,867 F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $233.75 to $233.91, inclusive. F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 19:01 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Exercise / conversionCommon Stock | 22,140 | $42.61 | $943,385.40 |
DisclosureSEC source: 0000707549-19-000145 · wf-form4_156840125508171.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 18:49 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GiftCommon Stock | 3,646 | $0.00 | $0.00 |
DisclosureSEC source: 0000707549-19-000141 · wf-form4_156805497572857.xml · nonDerivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,867 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 18:49 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | SaleCommon Stock | 5,000 | $229.08 | $1,145,375.00 |
DisclosureSEC source: 0000707549-19-000141 · wf-form4_156805497572857.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,513 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:06 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantEmployee Stock Option (Right to Buy) · Derivative | 5,948 | $176.75 Strike: $176.75 | $1,051,309.00 |
DisclosureSEC source: 0000707549-19-000039 · wf-form4_155182356606391.xml · derivative · entry 7 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,948 Underlying: Common Stock · 5,948 shares Expires 2026-03-01 F4 · derivative.exercise_date: The stock option becomes exercisable in three equal installments on 03/01/2020, 03/01/2021, and 03/01/2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:06 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantMarket-based Performance Restricted Stock Unit · Derivative | 3,717 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000707549-19-000039 · wf-form4_155182356606391.xml · derivative · entry 6 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,717 Underlying: Common Stock · 3,717 shares Expires not disclosed F3 · derivative.exercise_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 03/01/2022. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 02/01/2019 through 01/31/2022. F3 · derivative.expiration_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 03/01/2022. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 02/01/2019 through 01/31/2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:06 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 2,230 | $0.00 | $0.00 |
DisclosureSEC source: 0000707549-19-000039 · wf-form4_155182356606391.xml · nonDerivative · entry 5 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,397 F2 · shares: The Restricted Stock Units will vest in three equal installments on 03/01/2020, 03/01/2021, and 03/01/2022. F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:06 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 486 | $176.75 | $85,900.50 |
DisclosureSEC source: 0000707549-19-000039 · wf-form4_155182356606391.xml · nonDerivative · entry 4 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,167 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:06 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 799 | $176.75 | $141,223.25 |
DisclosureSEC source: 0000707549-19-000039 · wf-form4_155182356606391.xml · nonDerivative · entry 3 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,653 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:06 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 1,004 | $176.75 | $177,457.00 |
DisclosureSEC source: 0000707549-19-000039 · wf-form4_155182356606391.xml · nonDerivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,452 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:06 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 4,733 | $176.75 | $836,557.75 |
DisclosureSEC source: 0000707549-19-000039 · wf-form4_155182356606391.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,456 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 00:08 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Exercise / conversionMarket-based Performance Restricted Stock Unit · Derivative | 10,127 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000707549-19-000016 · wf-form4_155010286965378.xml · derivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,127 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 03/01/2019. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 02/01/2016 to 01/31/2019. F3 · derivative.expiration_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 03/01/2019. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 02/01/2016 to 01/31/2019. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 00:08 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Exercise / conversionCommon Stock | 11,233 | $0.00 | $0.00 |
DisclosureSEC source: 0000707549-19-000016 · wf-form4_155010286965378.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On 03/01/2016, the Reporting Person received a target grant of 10,127 Market-based Performance Restricted Stock Units vesting between 0% and 150% on 03/01/2019. The performance of this award was based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 02/01/2016 to 01/31/2019. The performance payout was approved at 110.93% of target. F2 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 22:25 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | SaleCommon Stock | 10,000 | $224.28 | $2,242,800.00 |
DisclosureSEC source: 0000707549-18-000072 · wf-form4_152184391502885.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Chief Legal Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,832 F1 · kind: The reporting person contributed LRCX common stock to an exchange fund in exchange for shares of the exchange fund. The LRCX common stock was valued at $224.28 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F1 · price: The reporting person contributed LRCX common stock to an exchange fund in exchange for shares of the exchange fund. The LRCX common stock was valued at $224.28 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F2 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 21:35 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | SaleCommon Stock | 1,835 | $212.64 | $390,194.40 |
DisclosureSEC source: 0000707549-18-000064 · wf-form4_152063132965743.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,832 F1 · price: The price reported in Column 4 is a weighted average sell price. These shares were sold in multiple transactions at prices ranging from $212.64 to $212.68, inclusive. F2 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:53 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,944 | $190.07 Strike: $190.07 | $559,566.08 |
DisclosureSEC source: 0000707549-18-000042 · wf-form4_152029401478930.xml · derivative · entry 5 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,944 Underlying: Common Stock · 2,944 shares Expires 2025-03-01 F4 · derivative.exercise_date: The stock option becomes exercisable in three equal installments on 03/01/2019, 03/01/2020, and 03/01/2021. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:53 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantMarket-based Performance Restricted Stock Unit · Derivative | 3,684 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000707549-18-000042 · wf-form4_152029401478930.xml · derivative · entry 4 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,684 Underlying: Common Stock · 3,684 shares Expires not disclosed F3 · derivative.exercise_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 03/01/2021. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 02/01/2018 through 01/31/2021. F3 · derivative.expiration_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 03/01/2021. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 02/01/2018 through 01/31/2021. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:53 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 2,947 | $0.00 | $0.00 |
DisclosureSEC source: 0000707549-18-000042 · wf-form4_152029401478930.xml · nonDerivative · entry 3 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,667 F2 · shares: The Restricted Stock Units will vest in three equal installments on 03/01/2019, 03/01/2020, and 03/01/2021. F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:53 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 798 | $190.07 | $151,675.86 |
DisclosureSEC source: 0000707549-18-000042 · wf-form4_152029401478930.xml · nonDerivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,720 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:53 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 1,003 | $190.07 | $190,640.21 |
DisclosureSEC source: 0000707549-18-000042 · wf-form4_152029401478930.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,518 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 23:31 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Exercise / conversionMarket-based Performance Restricted Stock Unit · Derivative | 8,064 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000707549-18-000033 · wf-form4_151856465138908.xml · derivative · entry 4 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,064 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On 2/11/15, the Reporting Person received a target grant of 8,064 Market-based Performance Restricted Stock Units vesting between 0% and 150% on 2/11/18. The performance of this award was based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 2/2/15 to 2/1/18. The performance payout was approved at 150% of target. F3 · derivative.exercise_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 2/11/18. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 2/2/15 to 2/1/18. F3 · derivative.expiration_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 2/11/18. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 2/2/15 to 2/1/18. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 23:31 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 1,066 | $165.87 | $176,817.42 |
DisclosureSEC source: 0000707549-18-000033 · wf-form4_151856465138908.xml · nonDerivative · entry 3 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,521 F2 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 23:31 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 5,114 | $165.87 | $848,259.18 |
DisclosureSEC source: 0000707549-18-000033 · wf-form4_151856465138908.xml · nonDerivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,587 F2 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 23:31 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Exercise / conversionCommon Stock | 12,096 | $165.87 | $2,006,363.52 |
DisclosureSEC source: 0000707549-18-000033 · wf-form4_151856465138908.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On 2/11/15, the Reporting Person received a target grant of 8,064 Market-based Performance Restricted Stock Units vesting between 0% and 150% on 2/11/18. The performance of this award was based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 2/2/15 to 2/1/18. The performance payout was approved at 150% of target. F2 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 23:27 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | SaleCommon Stock | 10,000 | $150.92 | $1,509,200.00 |
DisclosureSEC source: 0000707549-17-000088 · wf-form4_149826043172024.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,517 F1 · kind: The reporting person contributed LRCX common stock to an exchange fund in exchange for shares of the exchange fund. The LRCX common stock was valued at $150.92 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F1 · price: The reporting person contributed LRCX common stock to an exchange fund in exchange for shares of the exchange fund. The LRCX common stock was valued at $150.92 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F2 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 07, 2017 Filed Mar 8, 2017 20:29 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | SaleCommon Stock | 2,481 | $118.61 | $294,271.41 |
DisclosureSEC source: 0000707549-17-000043 · wf-form4_148900494361392.xml · nonDerivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,341 F2 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:29 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | SaleCommon Stock | 3,978 | $117.07 | $465,704.46 |
DisclosureSEC source: 0000707549-17-000043 · wf-form4_148900494361392.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,822 F1 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $117.04 to $117.07, inclusive. F2 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 21:21 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,832 | $0.00 Strike: $119.67 | $0.00 |
DisclosureSEC source: 0000707549-17-000036 · wf-form4_148848968746804.xml · derivative · entry 4 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,256 Underlying: Common Stock · 4,832 shares Expires 2024-03-01 F4 · derivative.exercise_date: 33.3% of the stock options will vest on 3/1/18, 3/1/19, and 3/1/20. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 21:21 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantMarket-based Performance Restricted Stock Unit · Derivative | 6,044 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000707549-17-000036 · wf-form4_148848968746804.xml · derivative · entry 3 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,235 Underlying: Common Stock · 6,044 shares Expires not disclosed F3 · derivative.exercise_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 3/01/20. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 2/01/17 to 1/31/20. F3 · derivative.expiration_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 3/01/20. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 2/01/17 to 1/31/20. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 21:21 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 4,835 | $0.00 | $0.00 |
DisclosureSEC source: 0000707549-17-000036 · wf-form4_148848968746804.xml · nonDerivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,800 F2 · shares: 33.3% of the RSUs will vest on 3/1/18, 3/1/19, and 3/1/20. F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 21:21 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 1,056 | $119.67 | $126,371.52 |
DisclosureSEC source: 0000707549-17-000036 · wf-form4_148848968746804.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,965 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 19:59 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 9,363 | $114.90 | $1,075,808.70 |
DisclosureSEC source: 0000707549-17-000028 · wf-form4_148831193175419.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,021 F1 · balance_after: Amount reported includes shares subject to unvested Restricted Stock Units. Read SEC document |
| February 17, 2017 Filed Feb 23, 2017 01:13 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Exercise / conversionMarket-based Performance Restricted Stock Unit · Derivative | 12,557 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000707549-17-000025 · wf-form4_148781241979038.xml · derivative · entry 3 O'Dowd Sarah A · CIK 0001447149 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,557 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: On 2/18/14, the Reporting Person received a target grant of 12,557 Market-based Performance Restricted Stock Units vesting between 0% and 150% on 2/18/17. The performance of this award was based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 2/18/14 to 2/17/17. The performance payout was approved at 150% of target. F3 · derivative.exercise_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 2/18/17. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 2/18/14 to 2/17/17. F3 · derivative.expiration_date: These Market-based Performance Restricted Stock Units vest between 0% and 150% on 2/18/17. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 2/18/14 to 2/17/17. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.